

09-18-01

Pnle Qmt  
0300 / SEQ #8  
D150  
CASE 4-30583A  
DT



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL 813100225 US  
Express Mail Label Number

September 17, 2001  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1632

AMLOT ET AL.

APPLICATION NO: 09/770,002

FILED: JANUARY 25, 2001

FOR: USE OF CD25 BINDING MOLECULES IN THE TREATMENT OF  
RHEUMATOID ARTHRITIS OR SKIN DISEASES

Assistant Commissioner for Patents  
Washington, D.C. 20231

AMENDMENT

Sir:

This is in response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide And/Or Amino Acid Sequences mailed on July 16, 2001. Please amend the application as follows:

IN THE SPECIFICATION:

Please replace the paragraph beginning at page 1, line 8, with the following rewritten paragraph:

--More specifically the present invention provides in a first aspect the use of a CD25 binding molecule which comprises at least one antigen binding site comprising at least one domain which comprises in sequence, the hypervariable regions CDR1, CDR2 and CDR3; said CDR1 having the amino acid sequence Arg-Tyr-Trp-Met-His (SEQ ID NO:1); said CDR2 having the amino acid sequence Ala-Ile-Tyr-Pro-Gly-Asn-Ser-Asp-Thr-Ser-Tyr-Asn-Gln-Lys-Phe-Glu-Gly (SEQ ID NO:2), and said CDR3 having the amino acid sequence Asp-Tyr-Gly-Tyr-Phe-Asp-Phe (SEQ ID NO: